Monitor for future equity grants under the new plan, which could signal management's confidence or need for retention. No immediate trading catalyst — the plan is standard governance and becomes effective in October 2026.
Price Chart
Executive Summary
Lifecore Biomedical filed an 8-K reporting the results of its 2026 annual meeting, where stockholders approved the 2026 Stock Incentive Plan and elected nine directors. The new plan authorizes 2.5 million new shares plus any forfeited shares from the prior 2019 plan, becoming effective October 16, 2026. This is a routine governance filing with no material financial impact.
Key Facts
- Stockholders approved the 2026 Stock Incentive Plan with 22,724,492 votes for, 392,825 against, and 13,086 abstentions.
- The 2026 Plan authorizes 2,500,000 new shares plus any forfeited shares from the 2019 Plan.
- The 2026 Plan becomes effective October 16, 2026, replacing the 2019 Stock Incentive Plan.
- All nine director nominees were elected, including two Series A Preferred directors elected solely by preferred stockholders.
- KPMG LLP was ratified as independent auditor for FY 2026 with 33,760,879 votes for.
- The say-on-pay advisory vote passed with 22,938,684 votes for.
Financial Impact
No financial impact; the 2026 Plan authorizes up to 2.5M new shares plus carryover from prior plan, but no immediate dilution or cash impact.
Risk Factors
- Potential future dilution from equity awards under the 2026 Plan.
- No material risk identified from this routine annual meeting filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001005286-26-000023 |
| Document: lfcr-20260604.htm | 0001005286-26-000023 |
| Document: 0001005286-26-000023-index-headers.html | 0001005286-26-000023 |
| Document: 0001005286-26-000023-index.html | 0001005286-26-000023 |
| Document: 0001005286-26-000023.txt | 0001005286-26-000023 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | 8-K | $4.44 $4.74 | ▲ +6.76% | ▲ +7.36% | $6.53 (+47.07%) |
Jul 2, 2026 13w ago | 8-K | $5.09 $4.36 | ▲ +14.34% | ▲ +13.93% | $6.53 (−28.29%) |
Jun 15, 2026 15w ago | Press Release | $5.49 $4.63 | ▼ −15.66% | ▼ −14.91% | $6.53 (+18.94%) |
Jun 5, 2026 17w ago | 8-K | $5.57 $5.05 | ▼ −9.34% | ▼ −10.97% | $6.53 (+17.24%) |
Jun 2, 2026 17w ago | Press Release | $5.45 $5.27 | ▼ −3.30% | ▼ −1.74% | $6.53 (+19.82%) |
May 6, 2026 21w ago | 8-K | $4.96 $5.67 | ▼ −14.31% | ▼ −11.53% | $6.53 (−31.65%) |
Mar 26, 2026 27w ago | Press Release | $3.87 $5.02 | ▲ +29.72% | ▲ +19.05% | $6.53 (+68.73%) |
Mar 16, 2026 28w ago | Press Release | $4.37 $5.20 | ▲ +18.99% | ▲ +15.21% | $6.53 (+49.43%) |
Mar 4, 2026 30w ago | Press Release | $7.02 $3.84 | ▼ −45.30% | ▼ −41.51% | $6.53 (−6.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access